• 1
    Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499511.
  • 2
    Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006; 130:1886900.
  • 3
    Diehl L, Schurich A, Grochtmann R, Hegenbarth S, Chen L, Knolle PA. Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance. Hepatology 2008; 47:296305.
  • 4
    Limmer A, Ohl J, Kurts C et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med 2000; 6:134854.
  • 5
    Kuniyasu Y, Marfani SM, Inayat IB, Sheikh SZ, Mehal WZ. Kupffer cells required for high affinity peptide-induced deletion, not retention, of activated CD8+ T cells by mouse liver. Hepatology 2004; 39:101727.
  • 6
    Jacques A, Bleau C, Martin JP, Lamontagne L. Intrahepatic endothelial and Kupffer cells involved in immunosuppressive cytokines and natural killer (NK)/NK T cell disorders in viral acute hepatitis. Clin Exp Immunol 2008; 152:298310.
  • 7
    Knolle PA, Gerken G. Local control of the immune response in the liver. Immunol Rev 2000; 174:2134.
  • 8
    Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48:32235.
  • 9
    Frink M, Hsieh YC, Thobe BM et al. TLR4 regulates Kupffer cell chemokine production, systemic inflammation and lung neutrophil infiltration following trauma-hemorrhage. Mol Immunol 2007; 44:262530.
  • 10
    Overland G, Stuestol JF, Dahle MK et al. Cytokine responses to fungal pathogens in Kupffer cells are Toll-like receptor 4 independent and mediated by tyrosine kinases. Scand J Immunol 2005; 62:14854.
  • 11
    Seki E, Tsutsui H, Nakano H et al. Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1β. J Immunol 2001; 166:26517.
  • 12
    Jiang W, Sun R, Wei H, Tian Z. Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of toll-like receptor 4 expression on macrophages. Proc Natl Acad Sci USA 2005; 102:1707782.
  • 13
    Thobe BM, Frink M, Hildebrand F et al. The role of MAPK in Kupffer cell toll-like receptor (TLR) 2-, TLR4-, and TLR9-mediated signaling following trauma-hemorrhage. J Cell Physiol 2007; 210:66775.
  • 14
    Wiegard C, Frenzel C, Herkel J, Kallen KJ, Schmitt E, Lohse AW. Murine liver antigen presenting cells control suppressor activity of CD4+CD25+ regulatory T cells. Hepatology 2005; 42:1939.
  • 15
    Gustot T, Lemmers A, Moreno C et al. Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 2006; 43:9891000.
  • 16
    Uhrig A, Banafsche R, Kremer M et al. Development and functional consequences of LPS tolerance in sinusoidal endothelial cells of the liver. J Leukoc Biol 2005; 77:62633.
  • 17
    Hayashi T, Kishiwada M, Fujii K et al. Lipopolysaccharide-induced decreased protein S expression in liver cells is mediated by MEK/ERK signaling and NFκB activation: involvement of membrane-bound CD14 and toll-like receptor-4. J Thromb Haemost 2006; 4:176373.
  • 18
    Martin-Armas M, Simon-Santamaria J, Pettersen I, Moens U, Smedsrod B, Sveinbjornsson B. Toll-like receptor 9 (TLR9) is present in murine liver sinusoidal endothelial cells (LSECs) and mediates the effect of CpG-oligonucleotides. J Hepatol 2006; 44:93946.
  • 19
    Wu J, Lu M, Meng Z et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007; 46:176978.
  • 20
    Lu M, Lohrengel B, Hilken G, Kemper T, Roggendorf M. Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes. J Virol 2002; 76:5867.
  • 21
    Katz SC, Pillarisetty VG, Bleier JI, Shah AB, DeMatteo RP. Liver sinusoidal endothelial cells are insufficient to activate T cells. J Immunol 2004; 173:2305.
  • 22
    Raz E. Organ-specific regulation of innate immunity. Nat Immunol 2007; 8:34.
  • 23
    Abe M, Tokita D, Raimondi G, Thomson AW. Endotoxin modulates the capacity of CpG-activated liver myeloid DC to direct Th1-type responses. Eur J Immunol 2006; 36:248393.
  • 24
    Ohtani M, Nagai S, Kondo S et al. Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood 2008; 112:63543.
  • 25
    Szabo G, Dolganiuc A, Mandrekar P. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology 2006; 44:28798.
  • 26
    Liew FY, Xu D, Brint EK, O’Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5:44658.
  • 27
    Hoebe K, Janssen EM, Kim SO et al. Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol 2003; 4:12239.
  • 28
    Zhou Z, Hoebe K, Du X, Jiang Z, Shamel L, Beutler B. Antagonism between MyD88- and TRIF-dependent signals in B7RP-1 up-regulation. Eur J Immunol 2005; 35:191827.
  • 29
    Kamon H, Kawabe T, Kitamura H et al. TRIF-GEFH1-RhoB pathway is involved in MHCII expression on dendritic cells that is critical for CD4 T-cell activation. EMBO J 2006; 25:410819.
  • 30
    Hayashi T, Beck L, Rossetto C et al. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest 2004; 114:2709.
  • 31
    Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004; 430:25763.
  • 32
    Tsung A, McCoy SL, Klune JR, Geller DA, Billiar TR, Hefeneider SH. A novel inhibitory peptide of Toll-like receptor signaling limits lipopolysaccharide-induced production of inflammatory mediators and enhances survival in mice. Shock 2007; 27:3649.
  • 33
    Visintin A, Halmen KA, Latz E, Monks BG, Golenbock DT. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol 2005; 175:646572.
  • 34
    McHutchison JG, Bacon BR, Gordon SC et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007; 46:13419.
  • 35
    Broering R, Wu J, Meng Z et al. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 2008; 48:91422.